Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 245,800 shares, a growth of 10.2% from the August 15th total of 223,100 shares. Based on an average daily trading volume, of 1,950,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 8.3% of the company’s stock are sold short.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Clearmind Medicine stock. Cornerstone Wealth Group LLC bought a new stake in shares of Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,000 shares of the company’s stock, valued at approximately $34,000. Cornerstone Wealth Group LLC owned approximately 1.18% of Clearmind Medicine at the end of the most recent quarter. Institutional investors and hedge funds own 96.05% of the company’s stock.
Clearmind Medicine Stock Performance
Shares of Clearmind Medicine stock traded down $0.02 during trading on Wednesday, hitting $1.32. 60,302 shares of the stock traded hands, compared to its average volume of 1,591,921. The stock’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.32. Clearmind Medicine has a 52-week low of $0.92 and a 52-week high of $10.35.
About Clearmind Medicine
Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
Featured Articles
- Five stocks we like better than Clearmind Medicine
- What is the FTSE 100 index?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.